Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614350 · ClinicalTrials.gov registry record · Phase 4
Pilot Study for Healing and Safety Outcomes in Gingival Recession
A Phase 4 study, sponsored by McGuire Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04614350: Completed Phase 4 study, sponsored by McGuire Institute.
NCT04614350 is a Phase 4 study that has completed, run by McGuire Institute. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614350, a Phase 4 study, has completed, sponsored by McGuire Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Prospective, randomized, within subjects-controlled design
Primary Outcome
tissue color
Interventions
- BIOLOGICAL Markman Biologics Microsurfaced ADM
- BIOLOGICAL AlloDerm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 4 |
What the finished NCT04614350 record still lists
NCT04614350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Markman Biologics Microsurfaced ADM is the first listed.
NCT04614350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04614350 about?
NCT04614350 is a clinical study titled "Pilot Study for Healing and Safety Outcomes in Gingival Recession". Prospective, randomized, within subjects-controlled design
What is the current status of trial NCT04614350?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-10-30. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04614350?
The interventions under investigation include: Markman Biologics Microsurfaced ADM (BIOLOGICAL), AlloDerm (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614350?
This trial is sponsored by McGuire Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04614350's enrollment target sits among peer trials
10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI